Inhibitors of Interleukin 4 Induced Protein 1 (IL4I1) as Potential Treatment for Cancer.

Published in: ACS medicinal chemistry letters (2023)

The invention in this patent application relates to piperazine-2,3-dione derivatives represented generally by formula 1. These compounds show activities as selective interleukin 4 induced protein 1 (IL4I1) inhibitors and may potentially be useful in preventing and treating IL4Il-related diseases, such as endometrial, ovarian, and triple negative breast cancers.

Keyphrases

high glucose
diabetic rats
drug induced
protein protein
oxidative stress
papillary thyroid
squamous cell carcinoma
endothelial cells
small molecule
risk assessment
preterm infants
squamous cell
endometrial cancer
climate change
human health
human milk
smoking cessation
stress induced
low birth weight